Advertisement

Topco Nasal Decongestant Drug Facts | Topcare Nasal Decongestant

21:26 EDT 19th June 2013 | BioPortfolio
Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Pseudoephedrine HCl 30 mg

Nasal decongestant

if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product.

do not use more than directed

ask a health professional before use.

In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)

adults and children 12 years and over take 2 tablets every 4 to 6 hours do not take more than 8 tablets in 24 hours
children ages 6 to 12 years take 1 tablet every 4 to 6 hours do not take more than 4 tablets in 24 hours
children under 6 years do not use this product in children under 6 years of age

carnauba wax, dibasic calcium phosphate, FD&C red no. 40 aluminum lake, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, silicon dioxide, titanium dioxide

1-888-423-0139

See New Dosing Directions

Maximum Strength

Non-Drowsy

Nasal Decongestant

Pseudoephedrine Hydrochloride

Nasal Decongestant

30 mg each

Nasal & Sinus Congestion

Sinus Pressure

actual size

Compare to Sudafed® Nasal Decongestant active ingredient

IMAGE 1a9e0336-c0c2-43f8-aeea-668d4a209714-01.jpg

Manufacturer

Topco Associates LLC

Active Ingredients

Source

Clinical Trials [ 425 Associated Clinical Trials listed on BioPortfolio]

Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-Allergic Rhinitis in Subjects With Persistent Nasal Congestion

Nasal glucocorticosteroids (GCS) are considered first-line therapy for both allergic and non-allergic rhinitis.1-3 Nasal congestion can persist despite maximum treatment with intranasal G...

Steady State Kinetics of l-Methamphetamine and Validation of Sensitivity of Dose Estimation

The intent of this study is to see if the rate that the body breaks down l-methamphetamine (l-MA) could be used as an accurate estimate for the rate that the body breaks down d-methampheta...

Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?

We hypothesize that those patients with purely seasonal allergic rhinitis will decongest better than those subjects with another cause contributing to their symptoms. These latter patient...

A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge

An H3 receptor antagonist should reduce the congestion associated with allergic rhinitis. A nasal allergen challenge will be given to patients to induce rhinitis symptoms and acoustic rhi...

Repeat Nasal Allergen Challenge

This is a non-drug, biomarker study to assess the utility of the model of repeated nasal allergen challenges in subjects with atopic rhinitis as a method of inducing an increased response...

PubMed Articles [ 1292 Associated PubMed Articles listed on BioPortfolio]

Septoplasty and decongestant improve distribution of nasal spray.

This study prospectively examined the intranasal distribution of nasal spray after nasal septal correction and decongestant administration. A cohort of 20 patients was assessed for the distribution of...

Comparative evaluation of nasal blood flow and airflow in the decongestant response to oxymetazoline.

Nasal blood flow (NBF) plays a crucial role in many physiological and pathological processes but its regulation and relation to other rhinological outcomes is poorly understood.

Decongestant use during pregnancy and its association with preterm delivery.

BACKGROUND: Despite the frequent intake of decongestants during pregnancy, only one study to date has evaluated the association of decongestants with preterm delivery, and it identified a reduced risk...

Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy.

BACKGROUND: Limited data is available for investigating the long-term safety and effects of intracoronary progenitor cell therapy in patients with acute myocardial infarction (AMI). OBJECTIVE: To asse...

Oral antihistamine/decongestant/analgesic combinations for the common cold.

Search BioPortfolio:
Advertisement

Drugs and Medication Quicklinks


Searches Linking to this Drug Record

Advertisement